Dr. Lana Bijelic is an oncological surgeon and specialist in peritoneal carcinomatosis who joined the Teknon Oncology Institute’s Carcinomatosis Surgical Group in 2019. She is certified by the American Board of Surgery and is a member of various scientific communities, including the American College of Surgeons and the Society of Surgical Oncology. She has held various research and clinical positions, and has been awarded numerous academic achievements.
Dr. Sullivan graduated in Medicine and Surgery from the National University of Rosario in 2005, specializing in Medical Oncology through the MIR at the Santa Creu i Sant Pau Hospital (HSCiSP, 2012) in Barcelona.
She received a post-MIR scholarship from the Ministry of Interior from HSPiSP (2012) and then a pre-doctoral scholarship from ISCiii (Rio Hortega – 2013-2015).
In 2014, he moved to Paris where he obtained a DUERTECC diploma at the Gustave Roussy University Hospital (Villejuif), followed by an ESMO scholarship (Georges Mathé Translator Scholarship), which he received in 2016.
Since January 2017, he has been working on the staff of the Medical Oncology Department of the HSCiSP. In the same year, he obtained his PhD from the Autonomous University of Barcelona.
Since 2015, he has been a member of the Board of Directors of the Spanish Lung Cancer Group (GECP). And since 2022, he has been the coordinator of the HSCiSP Committee on Neuroendocrine Tumors.
In November 2021, she joined the IOR Medical Oncology Service and is actively involved in various research projects in the Pangea Lab under the supervision of Dr. Molina.
Dr. Sullivan is involved in several clinical trials in lung cancer and neuroendocrine tumors, many of which have been presented at various international scientific meetings.
She has participated in national and international conferences and is an author and co-author of research articles published in influential journals.
She is currently a member of the Spanish Society of Medical Oncology (SEOM), GECP, European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE).